Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $1.0 million.

  • Axsome Therapeutics' Cash from Operations rose 10561.43% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.0 million, marking a year-over-year increase of 2384.85%. This contributed to the annual value of -$128.4 million for FY2024, which is 1149.02% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Cash from Operations is $1.0 million, which was up 10561.43% from -$32.4 million recorded in Q2 2025.
  • Axsome Therapeutics' Cash from Operations' 5-year high stood at $1.0 million during Q3 2025, with a 5-year trough of -$55.3 million in Q2 2023.
  • For the 4-year period, Axsome Therapeutics' Cash from Operations averaged around -$31.0 million, with its median value being -$30.4 million (2023).
  • As far as peak fluctuations go, Axsome Therapeutics' Cash from Operations tumbled by 81851.92% in 2024, and later soared by 10561.43% in 2025.
  • Axsome Therapeutics' Cash from Operations (Quarter) stood at -$27.6 million in 2022, then fell by 10.15% to -$30.4 million in 2023, then grew by 13.7% to -$26.2 million in 2024, then soared by 103.99% to $1.0 million in 2025.
  • Its Cash from Operations was $1.0 million in Q3 2025, compared to -$32.4 million in Q2 2025 and -$43.4 million in Q1 2025.